03 April 2014
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be giving two poster presentations at the AACR Annual Meeting in San Diego, 5-9th April 2014.
12 November 2013
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced that Penelope Ward has joined the Company in the role of Chief Medical Officer. Her appointment strengthens the Company’s expansion which recently saw the formation of a Scientific Advisory Board, appointment of additional R&D personnel and a move to a world-class biotech hub near Oxford.
02 October 2013
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has won ‘Best Biotech Fundraiser’ at this year’s OBN Awards ahead of shortlisted candidates e-Therapeutics and Heptares Therapeutics.
26 September 2013
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, is shortlisted for the ‘Best Biotech Fundraiser’ at this year’s OBN Awards. The awards will be held on the 1st October 2013 at the Ashmolean Museum in Oxford and will bring together the UK's emerging life sciences companies, corporate partners and investors to celebrate the achievements within the bioscience sector over the last year. To read more about the OBN Awards, please follow the link here.
21 August 2013
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced its engagement with the “Epigenetics’ Second Wind” debate at the SciBX Summit on Innovation in Drug Discovery and Development to be held in Boston, USA, on 29-30 October.
19 April 2013
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be making presentations at a number of key trade conferences including:
09 April 2013
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced the appointment of its scientific advisory board (SAB), which brings together world-leading expertise in target biology and drug research and development. The appointment of Karus’s SAB reflects the Company’s recent expansion and move to fully-integrated research and office facilities near Oxford.
17 December 2012
Karus Therapeutics Announces Collaboration with Babraham Institute to Explore PI3 Kinase Inhibitors in the Treatment of Inflammatory Diseases
06 September 2012
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, announces the closing of its Series B investment, which includes a first tranche of $7.6 million.
04 May 2010
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the closing of a £0.7 million financing. Investors include IP Venture Fund, Esperante, Drummond Paris and a number of existing and new Business Angels. The investment will be used to advance the development of Karus’s KAR2581 HDAC inhibitor and first‐in‐class drugs that selectively and potently target HDAC‐6 (KAR3000) and PI3‐Kinase p110β/p110δ (KAR4000). The company is focused on the development of these drugs to treat inflammatory diseases such as rheumatoid arthritis (RA), psoriasis and organ transplant rejection. With this investment, Karus will confirm the clinical candidates in it’s KAR2581, 3000 & 4000 programs and substantiate their potential as breakthrough treatments for chronic inflammatory diseases.
18 February 2010
Karus Therapeutics Ltd, a company engaged in the discovery and development of molecular-targeted drugs to treat inflammation and cancer, announced today it had extended its HDAC drug discovery programme to include small molecules that selectively inhibit HDAC-6, a target of emerging importance in the treatment of immune-inflammatory disorders.
23 September 2009
Karus Therapeutics Ltd, a company developing small molecule drugs to treat cancer and inflammation, has today announced that it has signed an agreement to collaborate with Professor Bart Vanhaesebroeck, at Queen Mary, University of London. Prof. Vanhaesebroeck is Centre Lead of the RAE 4-star rated Cell Signalling Laboratory. As part of the collaboration, Karus and Professor Vanhaesebroeck will be working to develop new small molecule inhibitors of selected isoforms of phosphoinositide 3-kinases (PI3K).
17 August 2009
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced that the company’s CSO, Dr Stephen Shuttleworth, will be making presentations at three key conferences in the coming weeks.
01 June 2009
Innovative pharmaceutical company Karus Therapeutics has today announced a collaborative research program with the Queen Elizabeth Hospital Renal Transplant Unit under the supervision of Lead Surgeon, Andrew Ready, Consultant Surgeon, Nicholas Inston, and Stephen Shuttleworth, CSO of Karus. The research program is designed to investigate the in vitro mechanisms-of-action of histone deacetylase inhibitors (HDIs) in specific leukocyte subsets, allogenic responses and in vivo models of transplant rejection.
04 May 2009
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the successful receipt of a Knowledge Transfer Partnership (KTP) award with King’s College London. The award will be used to support a collaborative program at the internationally renowned St John’s Institute of Dermatology at Guy’s Hospital under the joint supervision of the Head of Clinical Immunodermatology, Dr Richard Groves, and Dr Stephen Shuttleworth, Chief Scientific Officer of Karus Therapeutics. The KTP award will provide three years research and development support to Karus’s dermatology program.
06 April 2009
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced a second closing of its December 2008 investment, bringing the total amount raised to over £1 million and securing the company’s first US-based investor, New Hill Management LLC.
07 January 2009
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the closing of a £0.9 million investment. Investors include IP Venture Fund, Esperante, Drummond Paris and a number of Business Angels. The investment will be used to advance the development of new drugs to treat cancer and inflammatory diseases such as rheumatoid arthritis and psoriasis and includes innovative medicines based on Karus’s HDAC inhibitor (HDI) platform.
20 October 2008
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced that the company’s Chief Scientific Officer, Dr Stephen Shuttleworth, will be making a presentation at CHI’s Second Annual HDAC Inhibitors meeting in Boston, MA. This meeting is part of the Discovery on Target conference and brings together research and development teams from pharmaceutical and biotechnology companies that are active in the field of HDAC inhibitors.
02 April 2008
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced that Ann Hacker has joined the company’s board as an independent non-executive director. Ann brings substantial experience of senior management and corporate governance gained in major pharmaceutical and VC-backed biotechnology companies, which will support Karus’s continued growth and success.
01 January 2008
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the appointment of Dr Stephen J Shuttleworth FRSC to the position of Chief Scientific Officer. Dr Shuttleworth brings substantial R&D management experience gained from major life-science companies on both sides of the Atlantic and will play a key part in Karus’s ongoing success.
23 October 2007
Innovative pharmaceutical company Karus Therapeutics make presentations at two key industry conferences: the CHI „Discovery on Target‟ conference (Boston, MA) and the American Association for Cancer Research (AACR) conference (San Francisco, CA). In both presentations Professor Graham Packham, one of Karus’s founders, highlighted the progress made with Karus’s synthetic depsipeptide analogues and, in particular, presented in vivo data showing the dramatic improvements that Karus has recently made to the potency, safety and drug-like properties of these compounds.
01 October 2007
Innovative pharmaceutical company Karus Therapeutics Ltd has entered a co-development agreement with EOS SpA (Milan, Italy) to discover and develop new anti-cancer drugs based on Karus’s unique therapeutics platform. As part of the collaboration, Karus and EOS aim to develop a new drug through human Phase IIA cancer trials before securing a development and marketing partner.
01 July 2007
Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the closing of a £0.82 million investment, led by the company’s Chairman, Drummond Paris. Investors also included a consortium of high net worth individuals and reference Angels and the IP Venture Fund. The investment will be used to further develop drugs to treat cancer and inflammatory diseases based on Karus’s optimized HDAC inhibitor platform (OS-HDI).
12 October 2006
Innovative biopharmaceutical company Karus Therapeutics has appointed Drummond Paris as Chairman. He is currently President of Kowa Research Europe Ltd and was formerly CEO of Novartis Pharmaceuticals UK.
02 May 2006
Karus Therapeutics, an emerging biotechnology company and University of Southampton spinout, focused on developing innovative therapeutics to treat cancer and heart disease, has announced the appointment of Simon Kerry as its Chief Executive Officer (CEO).
Karus Therapeutics Limited
Genesis Building
Library Avenue
Harwell Campus
Oxfordshire OX11 0SG
Tel + 44 (0)1235 829140
Fax + 44 (0)1235 420517
E info@karustherapeutics.com
Registered in England & Wales No 05490954
VAT No 871 4126 33
© 2018 Karus Therapeutics
All Rights Reserved.
